Business Wire

HOGAN-LOVELLS

20.10.2021 12:52:05 CEST | Business Wire | Press release

Share
Hogan Lovells White Paper Calls for Flexibility as the EU Establishes Its First-ever Regulatory Framework Enabling the Launch of Autonomous Vehicles

Global law firm Hogan Lovells has today shared its recommendations on the future of Europe’s regulatory framework for autonomous vehicles (AVs), as the European Commission takes an important first step in submitting a Draft EU ADS Regulation to all 27 Member States ahead of a Public Consultation in November.

The regulatory framework published in late September 2021 will be used to help shape the future of AVs across the EU and will have far reaching implications on the AV industry in Europe for years to come.

The Draft EU ADS Regulation sets out the type-approval rules for AVs with regard to their automated driving system (ADS) to create a harmonised pathway for (SAE/ISO) “Level 4” or “fully automated” vehicles to be deployed on public roads across Member States – with no human driver. It also establishes aggregate safety metrics that will be used to benchmark performance, and ultimately will be used as a measurement for allowing AV testing and deployment.

The Hogan Lovells White Paper “The Road to Autonomous Vehicles” issued today identifies three key recommendations for a legal framework for AVs, which will guide regulatory developments at an EU and national level. They include:

  1. A broad, holistic and forward-looking approach to type-approval across Europe is important. The regulatory framework needs to be as flexible as possible. At a minimum, the existing system for type-approval should be used as a foundation and should not be undone for AVs/ADSs only.

  2. The assumption of regulatory responsibility and proof of safety concept should be considered as the decisive factor for regulations. Expertise is key when it comes to putting AVs onto public roads in the market and needs to be considered when allocating roles and responsibilities for different economic operators.

  3. Avoiding ambiguities (in particular to the existing regulatory framework), inconsistencies and the use of unclear terms and definitions that may lead to interpretation issues and delay the development and commercialisation of AVs.

The Draft EU ADS Regulation is part of a broader maturation in Europe’s AV regulatory environment. Other promising efforts are currently being made by France, Germany and the Netherlands, although Germany appears to be deviating from current existing broad definitions and a flexible approach applied at the EU level. The White Paper highlights that a harmonised approach across Europe providing adequate flexibility will be key for the long-term success of AVs.

Patrick Ayad, Global Leader of Mobility and Transportation at Hogan Lovells, said:

“This is a key piece of research on the future of Europe’s regulatory framework for autonomous vehicles.”

“We have an exciting opportunity to introduce autonomous vehicles in Europe. Current efforts made within Europe are encouraging and align well with the recommendations that we have made in our White Paper today. We need to take a broader and holistic approach to type approval as this will be even more valuable and beneficial for this purpose. Technological innovations, emerging new mobility solutions, as well as commercial and corporate partnerships changing the industry landscape call for a flexible framework – this needs to apply across Europe and individual Member States to work.”

Key highlights from the White Paper include:

- AV technology and the industry landscape are evolving rapidly. Developing an automated driving system (ADS) remains a highly-resource intensive endeavour, requiring extensive technical and specialised expertise.

- The challenge facing regulators is to provide a legal framework to allow for commercial deployment across Europe. This means setting appropriate “type-approval” requirements that meet the dual purposes of ensuring the technology is safe as well as facilitating commercial deployment in a way that will deliver the value the EU Commission has envisaged.

- Steps taken by the French, German and Dutch Governments are encouraging in that they seek to set out the legal basis for the approval of ISO/SAE Level 4 driving automation directly, and not lower-level human driver-assistance systems.

- The shift from conventional vehicles to AVs is a unique and disruptive scenario: it is the first time that not only the vehicle but also the driver (the ADS) are being regulated and type-approved.

- Innovation calls for flexibility. Regulating innovation calls for the same. An open and flexible approach has proven successful for AV testing over many years, building on - rather than replacing - existing regulatory concepts. This same lesson should be applied when it comes to the key question of defining which entity (or group of entities) should be responsible for presenting the AV - that is, the base vehicle and the ADS - to a regulator for type-approval.

- While the European Commission appears to be effectively addressing this issue under its forthcoming ADS Type Approval Implementing Act (which is expected to be in place by July 2022), it seems that the German Government takes a different approach under its current draft for an ordinance implementing the newly adopted changes to road traffic laws enabling regular operation of SAE/ISO Level 4 AVs, which, contrary to existing laws, introduces a new definition for “manufacturer” that refers to the “vehicle manufacturer”.

Hogan Lovells is one of the world's leading law firms in its dedication to an industry sector focused-approach, enabling us to advise our clients in a sector-focused manner, across practice groups, borders and industries.

In 2020, we created a new global Mobility and Transportation sector group, bringing together our already established industry sectors Automotive (and Mobility) and Aerospace and Defence as well as our new industry sector Transport and Logistics, to better represent the rapid changes facing the Mobility and Transportation world.

The full White Paper can be accessed here .

[Ends]

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye